| review article | Q7318358 |
| scholarly article | Q13442814 |
| P2093 | author name string | Raffin TA | |
| Koenig BA | |||
| Greely HT | |||
| McConnell LM | |||
| P2860 | cites work | Guidelines for the molecular genetics predictive test in Huntington's disease | Q22306172 |
| Alzheimer's disease after remote head injury: an incidence study | Q36901829 | ||
| Consensus statement on predictive testing for Alzheimer disease | Q41072133 | ||
| The clinical introduction of genetic testing for Alzheimer disease. An ethical perspective | Q41366395 | ||
| Genetic testing for BRCA1 and BRCA2: recommendations of the Stanford Program in Genomics, Ethics, and Society. Breast Cancer Working Group | Q45063550 | ||
| Utility of the apolipoprotein E genotype in the diagnosis of Alzheimer's disease. Alzheimer's Disease Centers Consortium on Apolipoprotein E and Alzheimer's Disease. | Q50907793 | ||
| Genetic testing for Alzheimer's disease 'not appropriate'. | Q53220070 | ||
| Statement on Use of Apolipoprotein E Testing for Alzheimer Disease | Q57319084 | ||
| Apolipoprotein E and Alzheimer's disease. A rapidly expanding field with medical and epidemiological consequences | Q71969708 | ||
| P433 | issue | 7 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | Alzheimer's disease | Q11081 |
| genomics | Q222046 | ||
| medical ethics | Q237151 | ||
| P304 | page(s) | 757-759 | |
| P577 | publication date | 1998-07-01 | |
| P1433 | published in | Nature Medicine | Q1633234 |
| P1476 | title | Genetic testing and Alzheimer disease: has the time come? Alzheimer Disease Working Group of the Stanford Program in Genomics, Ethics & Society | |
| P478 | volume | 4 |
| Q43053077 | Alzheimer's disease care and management: role of information technology |
| Q37029649 | Comparing test-specific distress of susceptibility versus deterministic genetic testing for Alzheimer's disease |
| Q35570857 | Differences between African American and White research volunteers in their attitudes, beliefs and knowledge regarding genetic testing for Alzheimer's disease |
| Q37423417 | Disclosure of APOE genotype for risk of Alzheimer's disease |
| Q34135724 | Estimating and disclosing the risk of developing Alzheimer‘s disease: challenges, controversies and future directions |
| Q38006981 | Ethical issues in Alzheimer's disease: an overview |
| Q53568371 | Ethical issues in genetics of mental disorders. |
| Q34575712 | Ethical, legal, and social dimensions of epilepsy genetics |
| Q33697740 | Genes and hypertension: where we are and where we should go. |
| Q35889850 | Genetic counseling and testing for Alzheimer disease: joint practice guidelines of the American College of Medical Genetics and the National Society of Genetic Counselors |
| Q50747108 | Genetic risk assessment for adult children of people with Alzheimer's disease: the Risk Evaluation and Education for Alzheimer's Disease (REVEAL) study. |
| Q36552904 | Genetics and dementia nosology |
| Q34032455 | Impact of gene patents and licensing practices on access to genetic testing for Alzheimer disease |
| Q34067007 | New insights into genetic aspects of Alzheimer's disease. Does genetic information make a difference in clinical practice? |
| Q58064570 | Pharmacogenomics and the challenge to privacy |
| Q39642852 | Privacy issues in personalized medicine. |
| Q35025023 | Risk factors for Alzheimer's disease: role of multiple antioxidants, non-steroidal anti-inflammatory and cholinergic agents alone or in combination in prevention and treatment |
| Q28370052 | The glutamatergic system and neurodegeneration in dementia: preventive strategies in Alzheimer's disease |
| Q35316963 | Using Alzheimer's disease as a model for genetic risk disclosure: implications for personal genomics |
| Q40494480 | Who seeks genetic susceptibility testing for Alzheimer's disease? Findings from a multisite, randomized clinical trial |
Search more.